

ROBERT W. FERGUSON
Attorney General
NOAH GUZZO PURCELL, WSBA #43492
Solicitor General
KRISTIN BENESKI, WSBA #45478
First Assistant Attorney General
COLLEEN M. MELODY, WSBA #42275
Civil Rights Division Chief
ANDREW R.W. HUGHES, WSBA #49515
LAURYN K. FRAAS, WSBA #53238
Assistant Attorneys General
TERA M. HEINTZ, WSBA #54921
(application for admission forthcoming)
Deputy Solicitor General
800 Fifth Avenue, Suite 2000
Seattle, WA 98104-3188
(206) 464-7744

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WASHINGTON**

STATE OF WASHINGTON, et al.,

Plaintiffs,

v.

UNITED STATES FOOD AND
DRUG ADMINISTRATION, et al.,

Defendants.

NO. 1:23-cv-03026-TOR

PLAINTIFF STATES' RESPONSE
TO DEFENDANTS' MOTION FOR
EXTENSION OF TIME

03/07/2023¹
Without Oral Argument

¹Due to the urgency of this matter, the Plaintiff States are filing this response well in advance of the March 6, 2023, deadline. *See* ECF No. 18. Because the Court's briefing schedule on this motion authorized a response and no further briefing, the Plaintiff States understand this motion to now be ripe for decision. *Id.*

I. INTRODUCTION

The Plaintiff States oppose Defendants’ Motion for Extension of Time (ECF No. 16) to respond to the Plaintiff States’ Motion for Preliminary Injunction (PI Motion) (ECF No. 3). The Plaintiff States moved for preliminary relief to protect access to critically important abortion and miscarriage care at a time when access to reproductive health care is under unprecedented attack. The FDA’s newly-enacted REMS restrictions unnecessarily limit who can prescribe, dispense, and obtain mifepristone for medication abortion, which unduly restricts access to this time-sensitive and extremely safe medication, leading to worse outcomes for patients and creating substantial and continuing burdens on providers and pharmacies. This is an urgent matter, and Defendants’ request for an extended briefing and hearing schedule should be denied.

II. ARGUMENT

A. The Fourteen-Day Time Period Prescribed in the Local Rules Controls

Local Civil Rule 7 provides Defendants with fourteen days to respond to the Plaintiff States’ PI Motion, i.e., until March 10, 2023. *See* LCivR 7(c)(2)(B), (b)(3). Extending this deadline requires a showing of “good cause.” Fed. R. Civ. P. 6(b)(1); *see also Algaier v. CMG Mortg., Inc.*, No. 13-CV-0380-TOR, 2014 WL 129286, at *12 (E.D. Wash. Jan. 14, 2014); *Dysart v. Ames*,

1 No. 13-CV-0261-TOR, 2014 WL 1364961, at *2 (E.D. Wash. Apr. 7, 2014).

2 Defendants fail to establish good cause for the extension they seek.

3 **B. Plaintiff States Did Not Delay in Moving for a Preliminary Injunction**

4 Defendants assert that the Plaintiff States “delay[ed]” in seeking a
 5 preliminary injunction—thus justifying a departure from the ordinary briefing
 6 schedule. ECF No. 16 at 2. This argument buries the most important facts. The
 7 REMS at the heart of this dispute did not take effect until January 3, 2023, and
 8 this challenge to final agency action was not ripe until that date. 5 U.S.C. § 704.
 9 In the time between the effective date of the REMS and the Plaintiff States’
 10 filings, this coalition of twelve states convened and drafted an 82-page Complaint
 11 and a 34-page PI Motion. In support of these filings, the Plaintiff States submitted
 12 approximately 800 pages of exhibits and evidence, including expert and technical
 13 evidence. Much of this evidence covers the impact of the REMS since its January
 14 2023 effective date—evidence that would have been impossible to provide had
 15 the Plaintiff States filed their PI Motion sooner. In short, the seven weeks to
 16 prepare and file Plaintiff States’ papers cannot be characterized as a “delay”—
 17 much less an “extreme delay”—under these circumstances. To the contrary, the
 18 timeline on which the Plaintiff States filed their Complaint and PI Motion were
 19 consistent with the level of urgency this case presents.

C. An Extension Would Result in Severe Prejudice to Plaintiff States

A delay in hearing the PI Motion will severely prejudice the Plaintiff States. The 2023 REMS restrictions are harming the Plaintiff States every day that they remain in effect. In today’s post-*Dobbs* landscape, in which the actions of anti-abortion state governments have strained access to abortion care even in states where abortion is a protected right, the 2023 REMS is exacerbating a crisis in abortion access of unprecedented proportions—warranting swift action by the Court.

Since *Dobbs*, the Plaintiff States have seen a huge influx of out-of-state patients seeking abortions. Cantrell Decl. ¶¶ 5, 7;² Dillon Decl. ¶¶ 8–13. For example, in January 2023, Planned Parenthood of Greater Washington and Northern Idaho saw a 75% increase in Idaho patients, as compared with January 2022. Dillon Decl. ¶ 10. “This includes a . . . 90% increase for medication abortion visits from Idaho.” *Id.* This increased patient volume has led to delays in abortion care and other consequences, including higher risks of complications, increased costs, and unnecessary trauma and stress for patients in the Plaintiff States, as well as increasing burdens on an already overtaxed healthcare system. *Id.* at ¶¶ 14–22; Godfrey Decl. ¶¶ 28, 31; [FDA’s] Opp’n to Pls.’ Mot. for a Prelim. Inj., *All. for Hippocratic Med. v. FDA*, No. 2:22-cv-00223-Z (N.D. Tex. Jan. 13, 2023), ECF No. 28 at 38–39; Compl. ¶ 142. By making mifepristone

²All declaration cites are to the declarations filed at ECF No. 4-1.

1 harder to prescribe, dispense, and obtain, the REMS exacerbates these growing
 2 harms. Gold Decl. ¶¶ 15–16, 27; Godfrey Decl. ¶¶ 17–22; Shih Decl. ¶¶ 21–29;
 3 Colwill Decl. ¶¶ 18–25; Nichols Decl. ¶ 38; Janiak Decl. ¶¶ 15–20; Downing
 4 Decl. ¶¶ 9–16; Henry Decl. ¶¶ 6–8; Lazarus Decl. ¶¶ 17–20; Compl. ¶¶ 136–138.

5 Further, the 2023 REMS works in concert with post-*Dobbs* legislation in
 6 anti-abortion states to limit access to abortion even in states where it is legal. As
 7 medical expert Marji Gold explains:

8 In the current hostile environment surrounding abortion care, which
 9 includes states passing bills that empower ordinary citizens to sue
 10 anyone they deem has “aided and abetted” a person seeking an
 11 abortion, clinicians may be reluctant to become certified and thus be
 12 identified as a person who prescribes mifepristone. Since the REMS
 13 requires certified prescribers to send their signed forms to *each*
 14 certified pharmacy at which they intend to prescribe, clinicians who
 wish to provide this care have reason to be concerned that an anti-
 abortion staff or pharmacist at a pharmacy might leak the
 confidential list and expose them to possible violence and/or civil or
 criminal liability. These concerns may be greater in communities
 with outspoken anti-abortion members, and thus decrease patient
 access to care.

15 Gold Decl. ¶ 18; *see also id.* at ¶ 19 (explaining the particular risk to patients who
 16 hold medical licenses in multiple states, including anti-abortion states); Prager
 17 Decl. ¶¶ 38–40; Shih Decl. ¶ 25.

18 For patients seeking to terminate a pregnancy, mere days can make a
 19 critical difference. The delays in treatment arising from the REMS—whether due
 20 to a lack of specifically “certified providers” (Godfrey Decl. ¶ 30) or pharmacies
 21 (Shih Decl. ¶ 27), a lack of access to technology required to e-sign the Patient
 22

1 Agreement Form (*id.* at ¶ 17), or lagging or incomplete REMS-required
 2 paperwork (DasGupta Decl. ¶ 10)—may cause patients to miss the narrow
 3 window for medication abortion. Compl. ¶ 81 (mifepristone is only approved for
 4 use up to 70-days’ gestation); Shih Decl. ¶ 17 (“[D]elaying the process even by
 5 a few days may make [some patients] ineligible to select medication abortion.”);
 6 Colwill Decl. ¶ 24. Even a few days’ delay may force such patients to choose
 7 between undergoing an invasive procedural abortion or carrying an unwanted
 8 pregnancy to term. Compl. ¶ 152 (detailing negative outcomes experienced by
 9 patients who are denied abortions); *id.* at ¶¶ 143–44 (explaining why surgical
 10 abortion may be inappropriate or inaccessible to certain patients).

11 These increasing harms are falling most heavily on those furthest from
 12 healthcare justice, including rural and poor communities that have inferior access
 13 to reproductive health care. Gold Decl. ¶ 23; Janiak Decl. ¶¶ 14, 25–29; Downing
 14 Decl. ¶ 17; Dillon Decl. ¶ 7; Godfrey Decl. ¶¶ 15, 17, 19, 32; Nichols Decl. ¶ 38;
 15 Compl. ¶ 121.

16 Finally, implementing the new REMS requirements has created ongoing
 17 burdens for state healthcare providers, resulting in mounting costs and an ongoing
 18 diversion of resources from patient care and other critical work. University of
 19 Washington personnel, for example, have expended hundreds of hours
 20 implementing the 2023 REMS, with many tasks still outstanding. Compl. ¶ 152;
 21 DasGupta Decl. ¶¶ 15–18; Godfrey Decl. ¶ 35; Prager Decl. ¶¶ 25–36; Reed
 22

Decl. ¶¶ 16–17; Singh Decl. ¶¶ 20–21. These harms are occurring now, because of the 2023 REMS, and they are urgent. Any further delay in addressing them will continue to prejudice the Plaintiff States.

D. Defendants Would Suffer No Prejudice in Adhering to the Ordinary Briefing Deadlines

By contrast, Defendants will suffer no prejudice if they are required to respond to the Plaintiff States’ motion on time. The U.S. Department of Justice’s Consumer Protection Branch has represented the FDA in a number of recent challenges to its regulation of mifepristone, including its imposition of the REMS. *See, e.g.*, [FDA’s] Opp’n to Pls.’ Mot. for a Prelim. Inj., *All. for Hippocratic Med. v. FDA*, No. 2:22-cv-00223-Z (N.D. Tex. Jan. 13, 2023), ECF No. 28 (Consumer Protection Branch defending challenge to FDA’s approval of mifepristone; preliminary injunction motion pending); *Chelius v. Wright*, No. 1:17-cv-00493-JAO-RT (D. Haw. May 7, 2021), ECF No. 148 (Consumer Protection Branch defending challenge to FDA’s previous version of REMS; stayed by joint agreement of parties after FDA agreed to re-examine the REMS); *Am. Coll. of Obstetricians & Gynecologists v. FDA*, 472 F. Supp. 3d 183, 189 (D. Md. 2020) (Consumer Protection Branch defending challenge to FDA’s previous version of REMS; preliminary injunction granted against FDA). At this point, lawyers with the Consumer Protection Branch have been litigating the facts and law surrounding the REMS for years. In light of their familiarity

1 with the issues, and the urgency facing the Plaintiff States, good cause does not
2 support an extended briefing schedule.

3 **E. The Plaintiff States' PI Motion Should Be Heard as Soon as Possible**

4 In recognition of the urgency of the matter, the Plaintiff States propose to
5 file a reply in support of their PI Motion within five days instead of the usual
6 seven, *see* LCivR 7(d)(2)(B), allowing this matter to be fully briefed for a hearing
7 on March 16, 2023, a date the Court had previously indicated may be available.
8 Although that hearing date is earlier than the default time period under
9 Local Rules, it is appropriate under Local Rule 7(i)(2)(C).

10 For all the reasons explained above and in the Plaintiff States' PI Motion,
11 this case involves an urgent issue, and good cause supports an expedited hearing.
12 LCivR 7(i)(2)(C)(1). Defendants' request for an extended briefing and hearing
13 schedule indicates that Defendants oppose the Plaintiff States' request for an
14 expedited hearing, LCivR 7(i)(2)(C)(2), but as detailed above, Defendants'
15 request for an extension should be denied. Finally, the Plaintiff States' proposed
16 March 16 hearing date is twenty days after the Motion for Preliminary Injunction
17 was filed, and therefore well within the bounds for expedited hearings.
18 LCivR 7(i)(2)(C)(3). Indeed, under the Plaintiff States' proposed five-day reply
19 turnaround, briefing will be complete before March 16 without affecting
20 Defendants' briefing schedule at all.

III. CONCLUSION

For the foregoing reasons, the Plaintiff States respectfully request that the Court deny Defendants' motion for an extension of time and require Defendants to file their response to the Plaintiff States' PI Motion no later than March 10, 2023, in accordance with the local rules.

DATED this 1st day of March 2023.

ROBERT W. FERGUSON
Attorney General

/s/ Kristin Beneski

NOAH GUZZO PURCELL, WSBA #43492
Solicitor General

KRISTIN BENESKI, WSBA #45478
First Assistant Attorney General

COLLEEN M. MELODY, WSBA #42275
Civil Rights Division Chief

ANDREW R.W. HUGHES, WSBA #49515

LAURYN K. FRAAS, WSBA #53238
Assistant Attorneys General

TERA M. HEINTZ, WSBA #54921

(application for admission forthcoming)
Deputy Solicitor General

800 Fifth Avenue, Suite 2000

Seattle, WA 98104-3188

(206) 464-7744

Attorneys for Plaintiff State of Washington

ELLEN F. ROSENBLUM
Attorney General of Oregon

/s/ Marc Hull

SANDER MARCUS HULL WSBA #35986

Senior Assistant Attorney General

YOUNGWO JOH OSB #164105

Assistant Attorney General

Trial Attorneys

1 Tel (971) 673-1880
2 Fax (971) 673-5000
3 marcus.hull@doj.state.or.us
4 youngwoo.joh@doj.state.or.us
5 *Attorneys for State of Oregon*

6 KRIS MAYES
7 Attorney General of Arizona

8 /s/ Daniel C. Barr
9 Daniel C. Barr (Arizona No. 010149)*
10 Chief Deputy Attorney General
11 Office of the Attorney General of Arizona
12 2005 N. Central Ave.
13 Phoenix, AZ 85004-1592
14 Phone: (602) 542-8080
15 Email: Daniel.Barr@azag.gov
16 *Attorney for Plaintiff State of Arizona*

17 PHILIP J. WEISER
18 Attorney General of Colorado

19 /s/ Eric Olson
20 ERIC OLSON, CO #36414*
21 Solicitor General
22 MICHAEL MCMASTER, CO #42368*
Assistant Solicitor General
Office of the Attorney General
Colorado Department of Law
1300 Broadway, 10th Floor
Denver, CO 80203
Phone: (720) 508-6000
Attorneys for Plaintiff State of Colorado

1 WILLIAM TONG
2 Attorney General of Connecticut

3 /s/ Joshua Perry
4 Joshua Perry*
5 Solicitor General
6 Office of the Connecticut Attorney General
7 165 Capitol Ave, Hartford, CT 06106
8 Joshua.perry@ct.gov
9 (860) 808-5372
10 Fax: (860) 808-5387
11 *Attorney for Plaintiff State of Connecticut*

12 KATHLEEN JENNINGS
13 Attorney General of Delaware

14 /s/ Vanessa L. Kassab
15 VANESSA L. KASSAB*
16 Deputy Attorney General
17 Delaware Department of Justice
18 820 N. French Street
19 Wilmington, DE 19801
20 302-683-8899
21 vanessa.kassab@delaware.gov
22 *Attorney for Plaintiff State of Delaware*

15 KWAME RAOUL
16 Attorney General of Illinois

17 /s/ Liza Roberson-Young
18 Liza Roberson-Young*
19 Public Interest Counsel
20 Office of the Illinois Attorney General
21 100 West Randolph Street
22 Chicago, IL 60601
Phone: (872) 272-0788
E.RobersonYoung@ilag.gov
Attorney for Plaintiff State of Illinois

1 DANA NESSEL
2 Attorney General of Michigan

3 /s/ Stephanie M. Service
4 Stephanie M. Service (P73305)*
5 Assistant Attorney General
6 Michigan Department of Attorney General
7 Health, Education & Family
8 Services Division
9 P.O. Box 30758
10 Lansing, MI 48909
11 (517) 335-7603
12 ServiceS3@michigan.gov
13 *Attorney for Plaintiff Attorney General of*
14 *Michigan*

15 AARON D. FORD
16 Attorney General of Nevada

17 /s/ Heidi Parry Stern
18 Heidi Parry Stern (Bar. No. 8873)*
19 Solicitor General
20 Office of the Nevada Attorney General
21 555 E. Washington Ave., Ste. 3900
22 Las Vegas, NV 89101
HStern@ag.nv.gov
Attorney for Plaintiff State of Nevada

RAÚL TORREZ
Attorney General of New Mexico

/s/ Aletheia Allen
Aletheia Allen*
Solicitor General
New Mexico Office of the Attorney General
201 Third St. NW, Suite 300
Albuquerque, NM 87102
AAllen@nmag.gov
Attorney for Plaintiff State of New Mexico

1 PETER F. NERONHA
2 Attorney General of Rhode Island

3 /s/ Julia C. Harvey

4 JULIA C. HARVEY #10529
5 Special Assistant Attorney General
6 150 S. Main Street
7 Providence, RI 02903
8 (401) 274-4400 x2103
9 *Attorney for Plaintiff State of Rhode Island*

10 CHARITY R. CLARK
11 Attorney General of Vermont

12 /s/ Eleanor L.P. Spottswood

13 ELEANOR L.P. SPOTTSWOOD*
14 Solicitor General
15 109 State Street
16 Montpelier, VT 05609-1001
17 (802)793-1646
18 eleanor.spottswood@vermont.gov
19 *Attorney for Plaintiff State of Vermont*

20 **Applications for pro hac vice admission*
21 *forthcoming*
22

CERTIFICATE OF SERVICE

I hereby certify that on March 1, 2023, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF System, which in turn automatically generated a Notice of Electronic Filing (NEF) to all parties in the case who are registered users of the CM/ECF system. The NEF for the foregoing specifically identifies recipients of electronic notice.

DATED this 1st day of March 2023, at Seattle, Washington.

/s/ Kristin Beneski

KRISTIN BENESKI, WSBA #45478
First Assistant Attorney General